Nu Skin Enterprises (NUS) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
15 Nov, 2025Executive summary
Q3 2025 revenue was $364.2 million, down 15.3% year-over-year, or 11.5% excluding Mavely, with EPS doubling to $0.34 from $0.17, reflecting disciplined execution amid macroeconomic pressures.
Customer, paid affiliate, and sales leader counts declined 10%, 13%, and 19% year-over-year, respectively, with sequential growth in Latin America and select segments.
Strategic focus is on launching the Prism iO intelligent wellness platform and expanding into India, with limited launches in Q4 2025 and full-scale rollouts in 2026.
Net income for Q3 2025 was $17.1 million, up from $8.3 million, driven by cost controls, lower tax rates, and the Mavely sale gain.
Sale of Mavely completed, impacting year-over-year comparisons and resulting in a $176.2 million pre-tax gain.
Financial highlights
Gross margin improved to 70.5% from 70.1% year-over-year; operating margin rose to 5.9% from 4.2%; selling expenses decreased to 35.8% of revenue from 39.0%.
Cash flow from operations was $27.7 million in Q3; cash and equivalents at $253.0 million at quarter-end.
Returned $3 million in dividends and repurchased $5 million in shares in Q3; $152.4 million remains under repurchase authorization.
Interest expense fell to $4.1 million from $6.5 million year-over-year.
Working capital as of September 30, 2025, was $293.7 million, up from $242.0 million at year-end 2024.
Outlook and guidance
Q4 2025 revenue projected between $365–$400 million, down 18% to 10% year-over-year, or 12% to 3% excluding Mavely; EPS guidance is $0.25–$0.35.
Full-year 2025 revenue guidance narrowed to $1.48–$1.51 billion, down 15%–13% (or 11%–9% excluding Mavely); adjusted EPS expected between $1.25 and $1.35.
No material revenue expected from Prism iO device sales in 2025; India market pre-opening in Q4 2025 with formal launch in H2 2026.
Capital expenditures for 2025 expected at $30–$35 million, focused on IT, plant expansion, and facility upgrades.
Focus remains on profitability, innovation, and growth acceleration in 2026, with Prism iO and India as key drivers.
Latest events from Nu Skin Enterprises
- 2025 EPS rose 51% despite revenue declines; 2026 growth expected from new launches and India expansion.NUS
Q4 202512 Feb 2026 - Q2 revenue fell 12.2% to $439.1M, with Rhyz up 32% and a $118.3M net loss on restructuring.NUS
Q2 20241 Feb 2026 - Q3 revenue fell 13.8%–14% YOY to $430.1M; Rhyz segments grew over 20% amid core declines.NUS
Q3 202415 Jan 2026 - Prysm iO and digital-first expansion in emerging markets are set to drive growth and stability.NUS
28th Annual ICR Conference 202612 Jan 2026 - Q4 revenue and EPS beat guidance but fell year-over-year; 2025 outlook remains cautious.NUS
Q4 202416 Dec 2025 - Proxy covers director elections, pay, incentive plan, auditor, and ESG progress.NUS
Proxy Filing2 Dec 2025 - Director elections, executive pay, incentive plan, and auditor ratification headline the 2025 meeting.NUS
Proxy Filing2 Dec 2025 - Q2 EPS surged to $0.43 as cost controls and Rhyz growth offset broad revenue declines.NUS
Q2 202523 Nov 2025 - Q1 revenue at $364.5M, adjusted EPS $0.23, Mavely sale lifts net income despite broad declines.NUS
Q1 202520 Nov 2025